Abstract: The present invention relates to liquid-crystal (LC) media as defined in claim 1, to the use thereof for optical, electro-optical and electronic purposes, in particular in LC displays, and to LC displays containing said LC media. The invention in particular relates to LC media with improved response time that enable energy saving displays.

Abstract: A liquid-crystal (LC) material having negative dielectric anisotropy and the use thereof for optical, electro-optical and electronic purposes, such as for example in LC displays, in particular energy saving displays based on the ECB, IPS or FFS effect, where the liquid crystal medium contains one or more compounds of formula I and one or more compounds compounds of formulae IIA, IIB, IIC and IID

Abstract: A liquid-crystalline (LC) media having positive dielectric anisotropy and tliquid-crystal displays (LCDs) containing these media, especially to displays addressed by an active matrix and in particular to energy efficient LC displays of the TN, PS-TN, STN, TN-TFT, OCB, IPS, PS-IPS, FFS, HB-FFS, XB-FFS, PS-FFS, SA-HB-FFS, SA-XB-FFS, polymer stabilised SA-HB-FFS, polymer stabilised SA-XB-FFS, positive VA or positive PS-VA type.

Abstract: An embodiment relates to a crystal polymorph of 8-bromo-2-(1-methylpiperidin-4-ylamino)-4-(4-phenoxyphenylamino)pyrido [4,3-d]pyrimidin-5(6H)-one hydrochloride which can effectively suppress FLT3 and has excellent stability even in a high temperature and humid environment, and a method for preparing same.

Abstract: Dielectrically positive liquid-crystalline media comprising a compound of the formula TINUVIN 770 and optionally one or more compounds of formula I, in which the parameters have the respective meanings indicated in the specification, and optionally one or more further dielectrically positive compounds and optionally one or more further dielectrically neutral compounds, and to liquid-crystal displays, especially active-matrix displays and in particular TN, IPS and FFS displays, containing these media.

Abstract: An embodiment relates to a crystal polymorph of 8-bromo-2-(1-methylpiperidin-4-ylamino)-4-(4-phenoxyphenylamino)pyrido[4,3 -d]pyrimidin-5 (6H)-one hydrochloride which can effectively suppress FLT3 and has excellent stability even in a high temperature and humid environment, and a method for preparing same.

Abstract: Pyridopyrimidinone derivatives and pharmaceutical compositions containing the same for use as an Axl inhibitor for the treatment of a disease or condition mediated by Axl such as cancer and metastasis, are disclosed. Also disclosed are methods for treating a Axl-mediated disease or condition by administering to a subject a therapeutically effective amount of the pyridopyrimidinone derivative.

Abstract: Dielectrically positive liquid-crystalline media comprising one or more compounds of each of the formulae S1 and S2, and one or more compounds selected from the group of the compounds of the formulae II and III and/or IV and/or VIII, in which the parameters have the meanings indicated in the specification, and optionally one or more further dielectrically positive compounds and optionally one or more further dielectrically neutral compounds. Also, liquid-crystal displays, especially active-matrix displays and in particular TN, IPS and FFS displays, containing these media.

Abstract: The present invention relates to dielectrically positive liquid-crystalline media comprising one or more compounds of the formula I and/or TINUVIN 770®, in which the parameters have the respective meanings indicated in the specification, and optionally one or more further dielectrically positive compounds and optionally one or more further dielectrically neutral compounds, and to liquid-crystal displays, especially active-matrix displays and in particular TN, IPS and FFS displays, containing these media.

Abstract: The present invention relates to dielectrically positive liquid-crystalline media comprising one or more compounds of the formula I and/or TINUVIN 770®, in which the parameters have the respective meanings indicated in the specification, and optionally one or more further dielectrically positive compounds and optionally one or more further dielectrically neutral compounds, and to liquid-crystal displays, especially active-matrix displays and in particular TN, IPS and FFS displays, containing these media.

Abstract: Compounds of Formula (I) and methods for inhibiting kinases, including spleen tyrosine kinases, are disclosed. Also disclosed are methods for treating a kinase-mediated disease or condition by administering to a subject a therapeutically effective amount of the compound of Formula (I).

Abstract: The present invention provides a new group of protein kinase inhibitors, pyrropyrimidine and pyrazolopyrimidine derivatives, and pharmaceutically acceptable salts and prodrugs thereof that are useful for treating cell proliferative disease and disorder such as cancer, autoimmune diseases, infection, cardiovascular disease and neurodegenerative disease and disorder. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor. The invention also provides useful intermediates generated during the syntheses of the pyrropyrimidine and pyrazolopyrimidine derivatives.

Abstract: Compounds of Formula (I) and methods for inhibiting kinases, including spleen tyrosine kinases, are disclosed. Also disclosed are methods for treating a kinase-mediated disease or condition by administering to a subject a therapeutically effective amount of the compound of Formula (I).

Abstract: The present invention provides a new group of protein kinase inhibitors, pyrido[4,3,-d]pyrimidin-5-one derivatives, and pharmaceutically acceptable salts thereof that are useful for intreating cell proliferative disease and disorder such as cancer, autoimmune diseases, infection, cardiovascular disease and neurodegenerative disease and disorder. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor. The invention also provides useful intermediates generated during the syntheses of the pyrido[4,3,-d]pyrimidin-5-one derivatives.

Abstract: The present invention provides a new group of protein kinase inhibitors, pyrropyrimidine and pyrazolopyrimidine derivatives, and pharmaceutically acceptable salts and prodrugs thereof that are useful for treating cell proliferative disease and disorder such as cancer, autoimmune diseases, infection, cardiovascular disease and neurodegenerative disease and disorder. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor. The invention also provides useful intermediates generated during the syntheses of the pyrropyrimidine and pyrazolopyrimidine derivatives.

Abstract: The present invention provides a new group of protein kinase inhibitors, pyrido[4,3,-d]pyrimidin-5-one derivatives, and pharmaceutically acceptable salts thereof that are useful for intreating cell proliferative disease and disorder such as cancer, autoimmune diseases, infection, cardiovascular disease and neurodegenerative disease and disorder. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor. The invention also provides useful intermediates generated during the syntheses of the pyrido[4,3,-d]pyrimidin-5-one derivatives.

Abstract: The present invention relates to RNA aptamers and uses thereof, more precisely RNA aptamers interfering the interaction of TCF with other proteins by binding specifically to ?-catenin, RNA aptamers binding specifically to HMG domains of TCF-I proteins and uses of the same. The RNA aptamer of the present invention can be effectively used for the development of an anticancer agent since it binds specifically to TCF-I to interrupt the interaction of TCF with ?-catenin involved in tumorigenesis and metastasis and the transcriptional activity of TCF-I in relation to oncogenes.